<DOC>
	<DOCNO>NCT00127088</DOCNO>
	<brief_summary>This prospective phase II study peri-operative docetaxel plus laparoscopic radical prostatectomy patient localize Gleason 7 pT2a-pT2b adenocarcinoma prostate risk relapse radical prostatectomy .</brief_summary>
	<brief_title>Study Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients older 18 year less 70 year Histologicallyproven Gleason 7 adenocarcinoma prostate pT2a pT2b disease base biopsy prostate More 2/3 positive biopsy 15 ≤ serum PSA &lt; 20 No previous carcinoma , except basalcell carcinoma skin Adequate renal function : measure calculated creatinine clearance &gt; 60 ml/min Absolute granulocyte count ≥ 1,500/mm3 , platelet ≥ 100,000 mm3 , bilirubin ≤ 1.5 fold upper normal value Signed informed consent . Patients infected Human Immunodeficiency Virus ( HIV ) Contraindication general anesthesia surgery Patients fit inclusion criterion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Patients localize Gleason 7 pT2a-pT2b adenocarcinoma prostate</keyword>
</DOC>